vs

Side-by-side financial comparison of FRIEDMAN INDUSTRIES INC (FRD) and Vericel Corp (VCEL). Click either name above to swap in a different company.

FRIEDMAN INDUSTRIES INC is the larger business by last-quarter revenue ($168.0M vs $92.9M, roughly 1.8× Vericel Corp). Vericel Corp runs the higher net margin — 25.0% vs 1.8%, a 23.2% gap on every dollar of revenue. On growth, FRIEDMAN INDUSTRIES INC posted the faster year-over-year revenue change (78.6% vs 23.3%). Vericel Corp produced more free cash flow last quarter ($12.8M vs $-6.3M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 13.3%).

Hellman & Friedman (H&F) is an American private equity firm founded in 1984 by Warren Hellman and Tully Friedman that makes investments primarily through leveraged buyouts as well as growth capital investments. It has focused its efforts on several core target industries including media, financial services, professional services and information services.

Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.

FRD vs VCEL — Head-to-Head

Bigger by revenue
FRD
FRD
1.8× larger
FRD
$168.0M
$92.9M
VCEL
Growing faster (revenue YoY)
FRD
FRD
+55.3% gap
FRD
78.6%
23.3%
VCEL
Higher net margin
VCEL
VCEL
23.2% more per $
VCEL
25.0%
1.8%
FRD
More free cash flow
VCEL
VCEL
$19.2M more FCF
VCEL
$12.8M
$-6.3M
FRD
Faster 2-yr revenue CAGR
VCEL
VCEL
Annualised
VCEL
34.6%
13.3%
FRD

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
FRD
FRD
VCEL
VCEL
Revenue
$168.0M
$92.9M
Net Profit
$3.0M
$23.2M
Gross Margin
2.3%
78.7%
Operating Margin
2.3%
24.1%
Net Margin
1.8%
25.0%
Revenue YoY
78.6%
23.3%
Net Profit YoY
364.1%
17.3%
EPS (diluted)
$0.43
$0.46

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FRD
FRD
VCEL
VCEL
Q4 25
$168.0M
$92.9M
Q3 25
$152.4M
$67.5M
Q2 25
$134.8M
$63.2M
Q1 25
$52.6M
Q4 24
$94.1M
$75.4M
Q3 24
$106.8M
$57.9M
Q2 24
$114.6M
$52.7M
Q1 24
$51.3M
Net Profit
FRD
FRD
VCEL
VCEL
Q4 25
$3.0M
$23.2M
Q3 25
$2.2M
$5.1M
Q2 25
$5.0M
$-553.0K
Q1 25
$-11.2M
Q4 24
$-1.2M
$19.8M
Q3 24
$-675.0K
$-901.0K
Q2 24
$2.6M
$-4.7M
Q1 24
$-3.9M
Gross Margin
FRD
FRD
VCEL
VCEL
Q4 25
2.3%
78.7%
Q3 25
1.9%
73.5%
Q2 25
5.2%
73.7%
Q1 25
69.0%
Q4 24
77.6%
Q3 24
-0.2%
71.9%
Q2 24
-1.2%
69.5%
Q1 24
68.9%
Operating Margin
FRD
FRD
VCEL
VCEL
Q4 25
2.3%
24.1%
Q3 25
1.9%
5.1%
Q2 25
5.2%
-3.2%
Q1 25
-24.3%
Q4 24
-1.3%
24.5%
Q3 24
-0.2%
-4.3%
Q2 24
-1.2%
-11.5%
Q1 24
-10.7%
Net Margin
FRD
FRD
VCEL
VCEL
Q4 25
1.8%
25.0%
Q3 25
1.5%
7.5%
Q2 25
3.7%
-0.9%
Q1 25
-21.4%
Q4 24
-1.2%
26.3%
Q3 24
-0.6%
-1.6%
Q2 24
2.2%
-8.9%
Q1 24
-7.5%
EPS (diluted)
FRD
FRD
VCEL
VCEL
Q4 25
$0.43
$0.46
Q3 25
$0.32
$0.10
Q2 25
$0.71
$-0.01
Q1 25
$-0.23
Q4 24
$-0.17
$0.40
Q3 24
$-0.10
$-0.02
Q2 24
$0.37
$-0.10
Q1 24
$-0.08

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FRD
FRD
VCEL
VCEL
Cash + ST InvestmentsLiquidity on hand
$3.0M
$137.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$142.2M
$354.6M
Total Assets
$311.9M
$488.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FRD
FRD
VCEL
VCEL
Q4 25
$3.0M
$137.5M
Q3 25
$4.6M
$135.4M
Q2 25
$2.1M
$116.9M
Q1 25
$112.9M
Q4 24
$1.1M
$116.2M
Q3 24
$2.5M
$101.7M
Q2 24
$4.1M
$102.5M
Q1 24
$110.6M
Stockholders' Equity
FRD
FRD
VCEL
VCEL
Q4 25
$142.2M
$354.6M
Q3 25
$139.3M
$321.9M
Q2 25
$137.3M
$306.8M
Q1 25
$295.5M
Q4 24
$127.3M
$292.0M
Q3 24
$128.8M
$257.5M
Q2 24
$129.7M
$243.0M
Q1 24
$233.9M
Total Assets
FRD
FRD
VCEL
VCEL
Q4 25
$311.9M
$488.0M
Q3 25
$311.3M
$453.3M
Q2 25
$219.1M
$435.6M
Q1 25
$424.6M
Q4 24
$210.3M
$432.7M
Q3 24
$209.2M
$390.4M
Q2 24
$222.8M
$376.8M
Q1 24
$356.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FRD
FRD
VCEL
VCEL
Operating Cash FlowLast quarter
$-4.7M
$15.0M
Free Cash FlowOCF − Capex
$-6.3M
$12.8M
FCF MarginFCF / Revenue
-3.8%
13.8%
Capex IntensityCapex / Revenue
1.0%
2.4%
Cash ConversionOCF / Net Profit
-1.56×
0.65×
TTM Free Cash FlowTrailing 4 quarters
$24.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FRD
FRD
VCEL
VCEL
Q4 25
$-4.7M
$15.0M
Q3 25
$434.0K
$22.1M
Q2 25
$15.5M
$8.2M
Q1 25
$6.6M
Q4 24
$22.2M
Q3 24
$10.2M
Q2 24
$-6.1M
$18.5M
Q1 24
$7.2M
Free Cash Flow
FRD
FRD
VCEL
VCEL
Q4 25
$-6.3M
$12.8M
Q3 25
$-2.0M
$19.5M
Q2 25
$13.7M
$81.0K
Q1 25
$-7.6M
Q4 24
$8.5M
Q3 24
$-9.2M
Q2 24
$-7.1M
$1.8M
Q1 24
$-6.8M
FCF Margin
FRD
FRD
VCEL
VCEL
Q4 25
-3.8%
13.8%
Q3 25
-1.3%
28.8%
Q2 25
10.2%
0.1%
Q1 25
-14.5%
Q4 24
11.2%
Q3 24
-15.9%
Q2 24
-6.2%
3.4%
Q1 24
-13.3%
Capex Intensity
FRD
FRD
VCEL
VCEL
Q4 25
1.0%
2.4%
Q3 25
1.6%
3.9%
Q2 25
1.3%
12.9%
Q1 25
27.0%
Q4 24
18.3%
Q3 24
33.5%
Q2 24
0.9%
31.8%
Q1 24
27.3%
Cash Conversion
FRD
FRD
VCEL
VCEL
Q4 25
-1.56×
0.65×
Q3 25
0.19×
4.35×
Q2 25
3.08×
Q1 25
Q4 24
1.12×
Q3 24
Q2 24
-2.36×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FRD
FRD

Prime Coil$152.0M90%
Manufactured Pipe$14.9M9%
Customer Owned$1.1M1%

VCEL
VCEL

MACI Implants And Kits$84.1M90%
Other$8.8M10%

Related Comparisons